<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Coronary artery revascularization in stable patients with diabetes mellitus
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Coronary artery revascularization in stable patients with diabetes mellitus
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Coronary artery revascularization in stable patients with diabetes mellitus
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard W Nesto, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Donald Cutlip, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Matthew A Cavender, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David M Nathan, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John Pepper, MA, MChir, FRCS, FESC
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Todd F Dardas, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Feb 24, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1198355879">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Coronary heart disease (CHD) is a major cause of morbidity and mortality among patients with diabetes mellitus. Compared with nondiabetic patients, individuals with diabetes, and especially those with kidney disease, are more likely to have CHD. Furthermore, patients with diabetes are more likely to have coronary artery disease that is complex, diffuse, and involves multiple vessels. Atherosclerosis tends to be more rapidly progressive and occurs at an earlier age. Diabetic patients with CHD have a lower long-term survival rate than nondiabetic patients with CHD [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1542.html" rel="external">
          "Prevalence of and risk factors for coronary heart disease in patients with diabetes mellitus"
         </a>
         .)
        </p>
        <p>
         Indications for the use of coronary artery revascularization are generally similar in patients with and without diabetes. However, patients with diabetes are at higher risk of future cardiovascular events following revascularization with either percutaneous coronary intervention or coronary artery bypass graft surgery [
         <a href="#rid2">
          2
         </a>
         ]. This increase in risk is likely due to more advanced coronary artery disease, more rapidly progressive disease, and comorbidities associated with diabetes [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="local">
          'Outcomes'
         </a>
         below.)
        </p>
        <p>
         This topic will focus on our approach to coronary artery revascularization in stable patients with diabetes. Issues related to medical versus interventional therapy for stable angina in nondiabetic patients and silent ischemia are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1557.html" rel="external">
          "Chronic coronary syndrome: Indications for revascularization"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1488.html" rel="external">
          "Silent myocardial ischemia: Epidemiology, diagnosis, treatment, and prognosis"
         </a>
         .)
        </p>
        <p>
         Our approach to revascularization in patients with acute coronary syndromes, with or without diabetes, is presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/46.html" rel="external">
          "Non-ST-elevation acute coronary syndromes: Selecting an approach to revascularization"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/80.html" rel="external">
          "Acute ST-elevation myocardial infarction: Selecting a reperfusion strategy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2037377422">
         <span class="h1">
          INDICATIONS FOR REVASCULARIZATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         We believe that the indications for revascularization in stable patients are similar for those with and without diabetes. The decision to proceed with revascularization, as opposed to continuing medical therapy, is made in three groups:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with activity-limiting symptoms despite maximum medical therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Active patients who want revascularization for improved quality of life compared with medical therapy, such as those who are not tolerating medical therapy or want to increase their activity level.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with anatomy for which revascularization has a proven survival benefit, such as significant left main coronary artery disease (CAD; greater than 50 percent luminal narrowing) or multivessel CAD with a reduction of left ventricular ejection fraction (LVEF) and a large area of potentially ischemic myocardium. (See
         <a class="medical medical_review" href="/z/d/html/1557.html" rel="external">
          "Chronic coronary syndrome: Indications for revascularization"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1138071783">
         <span class="h1">
          OUR APPROACH TO REVASCULARIZATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most patients with diabetes who have multivessel or complex disease and indications for revascularization (see
         <a class="local">
          'Indications for revascularization'
         </a>
         above), coronary artery bypass graft surgery (CABG) is preferable to percutaneous coronary intervention (PCI). This preference is based on the results of randomized clinical trials. The FREEDOM trial found that outcomes were improved with CABG. These findings are consistent with the SYNergy Between PCI With TAXus and Cardiac Surgery (SYNTAX) trial and a patient-level meta-analysis [
         <a href="#rid4">
          4,5
         </a>
         ]. For patients with low SYNTAX score (see
         <a class="medical medical_review" href="/z/d/html/1579.html" rel="external">
          "Revascularization in patients with stable coronary artery disease: Coronary artery bypass graft surgery versus percutaneous coronary intervention", section on 'Outcomes based on lesion severity'
         </a>
         ), single-, or two-vessel disease who have lesions that are focal and amenable to PCI, we believe that PCI is a reasonable alternative. In patients with three-vessel disease and a low SYNTAX score, it is not unreasonable to consider PCI, particularly for those with focal stenoses and increased surgical risk.
        </p>
        <p>
         Regardless of the procedure chosen, all patients with diabetes and CAD should be treated with aggressive risk factor reduction, including optimal management of diabetes, blood pressure control,
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         , lipid lowering therapy, and lifestyle changes including exercise, dietary modifications, and smoking cessation when indicated. (See
         <a class="medical medical_review" href="/z/d/html/1505.html" rel="external">
          "Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1730496422">
         <span class="h1">
          OUTCOMES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with diabetes comprise as many as 25 to 30 percent of those who undergo revascularization, consistent with the approximately 10 percent prevalence of diabetes in the general population and their two- to threefold increased risk for cardiovascular disease compared with the nondiabetic population. Procedural success is similar in the two groups, but long-term outcomes after revascularization with either percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG) are worse in diabetic compared with nondiabetic patients which may reflect the burden of comorbidities in patients with diabetes [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1898939660">
         <span class="h2">
          Revascularization versus medical therapy for stable angina
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the broad population of patients with diabetes, risk of death and future myocardial infarction are similar between revascularization and optimal medical therapy [
         <a href="#rid6">
          6-9
         </a>
         ]. Patients at high angiographic or clinical risk may benefit from revascularization [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         The best available evidence regarding a comparison of revascularization and optimal medical therapy comes from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI) 2D trial [
         <a href="#rid6">
          6,7
         </a>
         ]. In BARI 2D, 2368 patients with type 2 diabetes mellitus and nonacute ischemic heart disease (defined as either a ≥50 percent stenosis of a major epicardial coronary artery associated with a positive stress test or ≥70 percent stenosis and classic angina) were randomly assigned to either prompt revascularization (PCI or CABG) plus medical therapy or medical therapy only. The most appropriate mode of revascularization (PCI or CABG) was determined by the investigator prior to randomization. At five years, the primary end points of the rates of survival or freedom from major cardiovascular events (eg, death, myocardial infarction [MI], or stroke) did not differ significantly between the prompt revascularization group and the intensive medical therapy alone group (88.3 versus 87.8 percent and 77.2 versus 75.9 percent, respectively). However, in subgroup analysis, the rate of freedom from major cardiovascular events was significantly higher with CABG (77.6 versus 69.5 percent), predominantly attributable to a reduction in nonfatal MI. In the PCI stratum, there were no differences in major adverse cardiovascular events with prompt revascularization, when compared with intensive medical therapy alone (77.0 versus 78.9 percent).
        </p>
        <p>
         In the COURAGE trial, an initial revascularization strategy with PCI did not reduce the risk of death or MI when compared with an initial trial of medical therapy in a broad group of patients (see
         <a class="medical medical_review" href="/z/d/html/1557.html" rel="external">
          "Chronic coronary syndrome: Indications for revascularization", section on 'Indications'
         </a>
         ). However, patients treated with initial revascularization were more likely to be free from angina at one year (66 versus 58 percent). In the subgroup of patients with diabetes (n=766), patients treated with initial medical therapy had similar cardiovascular outcomes as patients treated with revascularization (HR 0.99; 95% CI 0.73-1.32) [
         <a href="#rid8">
          8,9
         </a>
         ].
        </p>
        <p>
         In the ISCHEMIA trial, patients with chronic coronary disease were randomly assigned to an invasive (medical therapy plus angiography and revascularization if feasible) or a conservative approach (medical therapy alone with revascularization if medical therapy failed). In this study, 43 percent of participants had diabetes. In a diabetes substudy of ISCHEMIA, participants with diabetes had increased hazards for death or MI over a median 3.1 years of follow-up (HR 1.49; 95% CI 1.31-1.70) [
         <a href="#rid11">
          11
         </a>
         ]. However, there was no difference in death or MI according to initial invasive strategy versus medical therapy. Similarly, in the REVIVED-SCIS2 trial of patients without angina who had left ventricular dysfunction with evidence of myocardial viability, 41 percent had diabetes [
         <a href="#rid12">
          12
         </a>
         ]. In this study, patients who had revascularization with percutaneous coronary intervention compared with medical therapy had similar risks of death or hospitalization for heart failure.
        </p>
        <p>
         In an attempt to understand further which patients might benefit from CABG, a risk score was developed from baseline angiographic (myocardial jeopardy index, total number of coronary lesions, prior coronary revascularization, and LVEF) and clinical variables (Framingham Risk Score) [
         <a href="#rid10">
          10
         </a>
         ]. Patients were then stratified into high- and low-risk subgroups using either angiographic or clinical variables or both. The composite endpoint of death, MI, or stroke occurred significantly less often in the CABG stratum than in the intensive medical therapy group (24.8 versus 36.8 percent) among those in the highest angiographic risk tertile, and this effect was even more pronounced in patients with both high angiographic and high clinical risk (27.1 versus 47.3 percent; hazard ratio 2.10, p = 0.0051). Although this analysis is limited by small sample size in subgroups and lack of validation of the angiographic risk score used, it suggests that in patients with diabetes, those at highest angiographic and clinical risk benefit the most from revascularization with CABG. In the 381 patients from the CABG stratum that were considered high risk, the rates of death, MI, or stroke at five years were 24.8 percent in the CABG arm and 36.8 percent in the medical therapy arm. In contrast, there were no differences between PCI and medical therapy in the high-risk PCI stratum (29.7 versus 29.9 percent).
        </p>
        <p class="headingAnchor" id="H1505619702">
         <span class="h2">
          After percutaneous coronary artery intervention
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among diabetic patients who undergo elective PCI, the procedural success rates are similar to patients without diabetes [
         <a href="#rid13">
          13-17
         </a>
         ]. However, patients with diabetes have increased rates of long-term restenosis and progression of coronary disease compared with patients without diabetes, as well as lower rates of event-free survival [
         <a href="#rid13">
          13-15,17-27
         </a>
         ]. The following are examples of this point:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In an analysis of 10,778 patients in the j-Cypher registry who underwent PCI with sirolimus-eluting stents, there were 966 patients with insulin-treated diabetes, 3404 with diabetes not treated with insulin, and 6378 without diabetes [
         <a href="#rid24">
          24
         </a>
         ]. At three years, the rate of target lesion revascularization was significantly higher in the insulin-treated and noninsulin-treated diabetes groups compared with those without diabetes (19, 14, and 10 percent, respectively). Predictors of restenosis in diabetic patients included smaller vessel caliber, greater length of the stented segment, and lower body mass index, similar to the broad population of patients with CAD.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The SYNTAX trial, which compared PCI with CABG in patients with complex CAD (left main and/or three vessel disease), included 452 patients with diabetes [
         <a href="#rid28">
          28
         </a>
         ]. At five-year follow-up, the rate of repeat revascularization of patients undergoing PCI (n = 231) was higher in patients with diabetes (29 versus 19 percent). Mortality was also increased in the diabetic population (20 versus 12 percent). (See
         <a class="medical medical_review" href="/z/d/html/1579.html" rel="external">
          "Revascularization in patients with stable coronary artery disease: Coronary artery bypass graft surgery versus percutaneous coronary intervention", section on 'Outcomes based on lesion severity'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1159892082">
         <span class="h2">
          After coronary artery bypass graft surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among patients who undergo elective CABG, the procedural short-term success rates are similar in patients with and without diabetes. However, during follow-up, death and adverse nonfatal outcomes after CABG are higher in patients with diabetes.
        </p>
        <p>
         In addition, the risk of sternal wound infection and renal failure is higher in patients with diabetes [
         <a href="#rid29">
          29-31
         </a>
         ]. It has been suggested that bilateral internal thoracic (mammary) artery grafting may be contraindicated in diabetic patients in whom the incidence of sternal wound infection is as high as 14 percent [
         <a href="#rid31">
          31
         </a>
         ]. Maintenance of strict glycemic control during the perioperative period and skeletonization of the internal mammary artery during harvesting are associated with lower rates of sternal wound infection [
         <a href="#rid32">
          32,33
         </a>
         ]. (See
         <a class="local">
          'Intraoperative and postoperative glycemic control'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/1585.html" rel="external">
          "Early noncardiac complications of coronary artery bypass graft surgery", section on 'Sternal wound infection and mediastinitis'
         </a>
         and
         <a class="local">
          'Internal thoracic artery grafts'
         </a>
         below.)
        </p>
        <p>
         Although diabetes does not appear to affect in-hospital mortality after CABG, short- and long-term survival after CABG are significantly reduced in diabetic patients. In different large observational studies, compared with nondiabetic patients, patients with diabetes had higher mortality rates at 30 days (5 versus 2.5 percent) and at 5 and 10 years (22 versus 12 percent and 50 versus 29 percent, respectively) [
         <a href="#rid29">
          29,30,34-42
         </a>
         ]. As with mortality, nonfatal coronary outcomes after CABG also may be somewhat more common in diabetic patients. In a report of over 12,000 patients, diabetes was associated with a significantly lower rate of freedom from PCI at 10 years (83 versus 86 percent) but no difference in either MI or additional CABG at 5 or 10 years [
         <a href="#rid40">
          40
         </a>
         ]. Another report evaluated 1615 patients who underwent CABG at a single center and had one or more repeat angiograms, and they were followed for ≥25 years [
         <a href="#rid41">
          41
         </a>
         ]. Diabetes was associated with a relative risk of 1.39 for progression of atherosclerosis or recurrent symptoms.
        </p>
        <p class="headingAnchor" id="H484825883">
         <span class="h2">
          PCI versus CABG
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most patients with diabetes and
         <strong>
          complex multivessel CAD
         </strong>
         who require revascularization (see
         <a class="local">
          'Revascularization versus medical therapy for stable angina'
         </a>
         above), the evidence suggests outcomes are improved with coronary artery bypass graft surgery (CABG). The evidence comes from the FREEDOM trial and subgroup analysis of the BARI 2D trial of patients with diabetes (see
         <a class="local">
          'Revascularization versus medical therapy for stable angina'
         </a>
         above) and subgroup analyses of the SYNTAX trial. (See
         <a class="medical medical_review" href="/z/d/html/1579.html" rel="external">
          "Revascularization in patients with stable coronary artery disease: Coronary artery bypass graft surgery versus percutaneous coronary intervention", section on 'Outcomes with coronary artery bypass graft surgery and percutaneous coronary intervention'
         </a>
         .)
        </p>
        <p>
         Prior to coronary revascularization, the patient should have the relative benefits and costs of PCI and CABG fully described.
        </p>
        <p class="headingAnchor" id="H2455517324">
         <span class="h3">
          Left main coronary artery disease and SYNTAX score ≤32
         </span>
         <span class="headingEndMark">
          —
         </span>
         Similar to patients with without diabetes, CABG or PCI may be reasonable revascularization approaches in those with diabetes. Factors such as the complexity of associated disease have been identified that may help in deciding between the two. (See
         <a class="medical medical_review" href="/z/d/html/1555.html" rel="external">
          "Left main coronary artery disease", section on 'Percutaneous coronary intervention versus coronary artery bypass graft surgery'
         </a>
         .)
        </p>
        <p>
         The EXCEL trial randomized patients with significant left main coronary artery stenosis and low/intermediate SYNTAX score (≤32). All patients had to be candidates for both PCI or CABG. [
         <a href="#rid2">
          2
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/1555.html" rel="external">
          "Left main coronary artery disease", section on 'Randomized trials'
         </a>
         ). In EXCEL, there were 1905 patients (554 patients with diabetes) assessed to have
         <strong>
          low or intermediate
         </strong>
         CAD complexity based on a SYNTAX score ≤32. The following findings were noted in EXCEL:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The three-year composite primary end point (all-cause death, stroke, or MI) was higher in patients with diabetes compared with those without (20.0 versus 12.9 percent; hazard ratio [HR] 1.60, 95% CI 1.26-2.04).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with diabetes, the rate of the primary end point was similar between those who received PCI or CABG (20.7 versus 19.3 percent, respectively; HR 1.03, 95% CI 0.71-1.50).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The rate of all-cause death was higher in those treated with PCI (13.6 versus 9.0 percent, respectively; p = 0.046), and there was no significant interaction regarding diabetes status. However, there were only 59 total deaths in the subgroup with diabetes (n = 38 [PCI] versus n = 21 [CABG]), so the study was underpowered to evaluate death as a single endpoint. (See
         <a class="medical medical_review" href="/z/d/html/1579.html" rel="external">
          "Revascularization in patients with stable coronary artery disease: Coronary artery bypass graft surgery versus percutaneous coronary intervention", section on 'Outcomes based on lesion severity'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4222139541">
         <span class="h3">
          Multivessel or complex disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the general population of patients who require coronary revascularization, CABG is preferred to PCI in many patients with multivessel disease. In patients without multivessel coronary artery disease, complex anatomy such as distal left main or proximal left anterior descending coronary artery stenosis, or heavily calcified lesions in tortuous vessels, may influence decision making in favor of CABG. (See
         <a class="medical medical_review" href="/z/d/html/1579.html" rel="external">
          "Revascularization in patients with stable coronary artery disease: Coronary artery bypass graft surgery versus percutaneous coronary intervention", section on 'Our approach'
         </a>
         .)
        </p>
        <p>
         The FREEDOM trial is the largest relevant randomized controlled trial evaluating PCI and CABG in patients with multivessel coronary artery disease. In the FREEDOM trial, 1900 patients with diabetes and multivessel CAD (83 percent three-vessel disease) were randomly assigned to either PCI with early generation drug-eluting stents (DES) or CABG. Both groups received optimal medical therapies for the secondary prevention of cardiovascular disease [
         <a href="#rid43">
          43
         </a>
         ]. The median follow-up among survivors was 3.8 years. The following findings were noted:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The primary composite outcome of death from any cause, nonfatal MI, or nonfatal stroke occurred significantly more often in the PCI group at five years (26.6 versus 18.7 percent; absolute difference of 7.9 percent, 95% CI 3.3-12.5). The benefit from CABG existed in all SYNTAX score subgroups. (See
         <a class="medical medical_review" href="/z/d/html/1579.html" rel="external">
          "Revascularization in patients with stable coronary artery disease: Coronary artery bypass graft surgery versus percutaneous coronary intervention", section on 'Outcomes based on lesion severity'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         With regard to the individual components of the composite end point, all-cause mortality and MI were significantly higher with PCI (16.3 versus 10.9 and 13.9 versus 6.0 percent, respectively), whereas stroke occurred significantly less often (2.4 versus 5.2 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At one year, there was a higher rate of repeat revascularization in the PCI group (12.6 versus 4.8 percent; HR 2.74, 95% CI 1.91-3.89).
        </p>
        <p>
        </p>
        <p>
         The SYNTAX trial compared first-generation DES with CABG in patients with multivessel coronary artery disease. In this trial, 1800 patients with three-vessel or left main coronary artery disease were randomized to paclitaxel-eluting stent or CABG. A total of 452 patients (25 percent) had diabetes. The following findings were noted:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the overall trial cohort at 12 months, major adverse cardiac or cerebrovascular events were higher in the PCI group (17.8 percent [PCI] versus 12.4 percent [CABG]; p = 0.002). The results were consistent in the subgroup with diabetes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At three years, in the cohort with diabetes, major adverse cardiac and cerebrovascular event rates were higher with PCI (37 percent [PCI] versus 22.9 percent [CABG]; p = 0.002). The need for repeat revascularization was significantly higher in patients with diabetes treated with PCI (28 percent [PCI] versus 12.9 percent [CABG]; p&lt;0.001) [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At 10 years, there were no significant differences in death between patients treated with PCI compared with CABG (27 percent [n = 244 with PCI] versus 24 percent [n = 211 with CABG]; p = 0.09). In the cohort with diabetes, in whom 10-year outcomes were available in 452, a total of 150 had died. There were no differences in the risk of death at 10 years in patients treated with PCI compared with CABG (HR 1.10; 95% CI 0.80-1.52) [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         These data should be interpreted with the understanding that the DES used in this trial (paclitaxel-eluting) has been shown to be less effective and inferior to the current generation of DES.
        </p>
        <p>
         A patient-level meta-analysis that included data from 11 randomized trials evaluating PCI and CABG provides additional evidence for the superiority of CABG for patients with diabetes and multivessel coronary artery disease [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mortality at five years was significantly higher with PCI in those patients with diabetes and multivessel coronary artery disease compared with CABG (15.5 versus 10.0 percent; HR 1.48; 95% CI 1.019-1.84; p = 0.0004).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There was no difference in mortality between PCI and CABG in patients with multivessel without diabetes (HR 1.08; 95% CI 0.86-1.36; p = 0.49). (See
         <a class="medical medical_review" href="/z/d/html/1579.html" rel="external">
          "Revascularization in patients with stable coronary artery disease: Coronary artery bypass graft surgery versus percutaneous coronary intervention", section on 'Outcomes with coronary artery bypass graft surgery and percutaneous coronary intervention'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3788912810">
         <span class="h3">
          One- or two-vessel disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with single-vessel or noncomplex disease for whom revascularization is indicated (see
         <a class="local">
          'Indications for revascularization'
         </a>
         above), PCI is a reasonable choice. While this issue has not been specifically studied, most of our experts prefer PCI to CABG.
        </p>
        <p class="headingAnchor" id="H2576076131">
         <span class="h3">
          Previous coronary artery bypass graft surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal revascularization approach in diabetic patients with post-CABG angina is not known. The general approach to the management of post-CABG angina is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1588.html" rel="external">
          "Late recurrent angina pectoris after coronary artery bypass graft surgery", section on 'Management'
         </a>
         .)
        </p>
        <p>
         PCI is a reasonable first choice for most patients with diabetes and unacceptable angina (with appropriate anatomy) after CABG. Repeat CABG can be considered for patients with multigraft failure or no prior placement of a left internal thoracic artery graft.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          PCI CONSIDERATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among patients with diabetes who undergo percutaneous coronary intervention (PCI), outcomes such as the rates of target lesion revascularization, MI, or survival may be influenced by the stent type as well as diabetes-related factors.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Stent type
         </span>
         <span class="headingEndMark">
          —
         </span>
         Similar to the general population of patients who undergo PCI with stent placement, patients who receive current generation drug-eluting stents (DES) have a lower rate of restenosis and subsequent revascularization than those who receive either bare metal stents or early generation DES [
         <a href="#rid45">
          45-58
         </a>
         ]. The newest generation of ultra-thin-strut stents may reduce target lesion failure and MI [
         <a href="#rid59">
          59
         </a>
         ]. However, a patient-level meta-analysis of ultra-thin stents in patients with diabetes did not demonstrate increased benefit [
         <a href="#rid60">
          60
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1575.html" rel="external">
          "Intracoronary stents: Stent types", section on 'Ultra-thin-strut bioresorbable drug-eluting stents'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Diabetes-related factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several diabetes-related clinical factors have been evaluated for their impact on outcome after PCI:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The rate of restenosis after PCI in diabetic patients may be lower in the setting of lower glycemia. This was suggested in an analysis from 2004 of 239 patients (179 with diabetes) who underwent elective PCI (67 percent with stenting) after measurement of glycated hemoglobin (HbA1c) [
         <a href="#rid61">
          61
         </a>
         ]. Diabetic patients with a preprocedural HbA1c ≤7 percent had a rate of target vessel revascularization at 12 months that was comparable to that in nondiabetic patients (15 versus 18 percent), while diabetic patients with an HbA1c &gt;7 percent had a significantly higher rate of target vessel revascularization (34 percent). Generalization is limited by the study design (non-randomized observational study), its small size, and potential for confounding.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The experimental observations that the thiazolidinediones inhibit vascular smooth muscle cell proliferation and migration and reduce intimal proliferation after vascular injury provided the rationale for assessing their effect on limiting in-stent restenosis in both nondiabetic and diabetic patients. (See
         <a class="medical medical_review" href="/z/d/html/1757.html" rel="external">
          "Thiazolidinediones in the treatment of type 2 diabetes mellitus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The potential efficacy of this approach has been evaluated in two small randomized trials in which patients with type 2 diabetes who underwent PCI with stenting were randomly assigned to either a thiazolidinedione (
         <a class="drug drug_general" data-topicid="10216" href="/z/d/drug information/10216.html" rel="external">
          pioglitazone
         </a>
         or
         <a class="drug drug_general" data-topicid="10249" href="/z/d/drug information/10249.html" rel="external">
          rosiglitazone
         </a>
         ) or placebo [
         <a href="#rid62">
          62,63
         </a>
         ]. In both studies, the rate of angiographic restenosis was significantly lower in the thiazolidinedione group. Further studies are required to confirm the efficacy and safety of this approach, particularly with the use of DES since stent technology has evolved since the conduct of these studies.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1291718761">
         <span class="h2">
          Lipid-related factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lipid-lowering therapy is the cornerstone of secondary prevention measures to reduce future coronary events in patients following PCI. (See
         <a class="medical medical_review" href="/z/d/html/1505.html" rel="external">
          "Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk", section on 'Dyslipidemia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h1">
          CORONARY ARTERY BYPASS GRAFT SURGERY CONSIDERATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h2">
          Comorbidities
         </span>
         <span class="headingEndMark">
          —
         </span>
         The rates of long-term death and adverse nonfatal outcomes after coronary artery bypass graft surgery (CABG) are higher in patients with diabetes compared with those without diabetes. (See
         <a class="local">
          'Outcomes'
         </a>
         above.)
        </p>
        <p>
         A variety of factors contribute to the worse prognosis. Diabetic patients who undergo CABG have a worse risk profile, tending to be older with more three-vessel disease and lower LVEF than nondiabetic patients [
         <a href="#rid34">
          34,36,39,64
         </a>
         ].
        </p>
        <p>
         Comorbidities of diabetes influence post-CABG survival. This was illustrated in a cohort of 36,641 patients undergoing isolated CABG between 1992 and 2001: 70 percent did not have diabetes, 22 percent had diabetes without renal failure (requiring preoperative dialysis) or vascular disease (peripheral or cerebrovascular), and 8 percent had diabetes with renal failure and/or vascular disease [
         <a href="#rid65">
          65
         </a>
         ]. The annual mortality rate for patients without diabetes (3.1 percent) was similar to that for patients with diabetes but no renal failure or vascular disease (4.4 percent). Patients with diabetes who had renal failure and/or vascular disease had a significantly higher annual mortality rate (9.4 percent).
        </p>
        <p>
         Another observational study of 905 patients found (on multivariate analysis) that an elevated serum creatinine (not renal failure as in the prior study) was an independent predictor of five-year mortality (adjusted hazard ratio 1.5) [
         <a href="#rid66">
          66
         </a>
         ]. Proteinuria was also an independent predictor of mortality.
        </p>
        <p>
         Preoperative glycemic control is associated with outcomes following CABG. In 3555 consecutive patients undergoing elective CABG at an academic medical center between 2002 and 2006, increasing HbA1c was associated with increased risk of mortality, MI, and deep sternal wound infection [
         <a href="#rid67">
          67
         </a>
         ]. After adjusting for potential confounders, there was an increased risk of mortality (odds ratio 1.40; 95% CI 1.06-1.86) for every 1 percent increase in HbA1c.
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h2">
          Internal thoracic artery grafts
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients undergoing CABG, including those with diabetes, should receive an internal thoracic (mammary) artery (ITA) graft to improve survival. (See
         <a class="medical medical_review" href="/z/d/html/1554.html" rel="external">
          "Coronary artery bypass graft surgery: Graft choices", section on 'Arterial grafts'
         </a>
         .)
        </p>
        <p>
         In addition, we prefer bilateral to single ITA grafting for many patients with diabetes based on two observational studies. This recommendation is made despite the fact that the rate of sternal wound infection may be modestly increased with bilateral compared with single ITA grafting and that diabetes may be a risk factor for the development of postoperative mediastinitis [
         <a href="#rid68">
          68,69
         </a>
         ]. (See
         <a class="local">
          'After coronary artery bypass graft surgery'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7014.html" rel="external">
          "Postoperative mediastinitis after cardiac surgery", section on 'Risk factors'
         </a>
         .)
        </p>
        <p>
         The issue of whether bilateral ITA improves outcomes compared with single ITA in patients with diabetes was evaluated in a study of 1107 consecutive patients who received either a single or bilateral ITA [
         <a href="#rid70">
          70
         </a>
         ]. After propensity matching, two cohorts of 414 individuals were created. There was no significant difference between the single and bilateral ITA groups in operative mortality (2.4 versus 3.1 percent, respectively), sternal wound infection (1.7 versus 3.1 percent), or total complications (17.1 percent). However, late median survival was significantly lower with single ITA grafting (9.8 versus 13.1 years). Similar improvement in long-term survival after placement of bilateral ITA among patients with diabetes was reported in another 2012 observational study [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
         Radial grafts should be considered in patients undergoing CABG, particularly in those patients with diabetes who are relatively young. In a meta-analysis of six trials evaluating the use of radial artery grafts in patients undergoing CABG (mean age 67 and 35 percent with diabetes), the use of radial grafts reduced the rate of death, MI, or revascularization when compared with saphenous vein grafts (hazard ratio [HR] 0.67, 95% CI 0.49-0.90) [
         <a href="#rid72">
          72
         </a>
         ]. Radial arterial grafts were also at lower risk of graft failure (HR 0.44; 95% CI 0.28-0.70). Outcomes were similar in patients with and without diabetes.
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          Intraoperative and postoperative glycemic control
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most patients with diabetes, we attempt intensive glycemic control intra- and postoperatively to improve both cardiac and noncardiac outcomes in diabetic patients after CABG [
         <a href="#rid32">
          32,73,74
         </a>
         ]. The following observations illustrate the range of findings:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a prospective trial, 141 patients with diabetes who were undergoing CABG were randomly assigned to tight glycemic control (125 to 200 mg/dL [6.9 to 11.1 mmol/L]) with a glucose-insulin-potassium (GIK) infusion or standard therapy with intermittent subcutaneous insulin [
         <a href="#rid74">
          74,75
         </a>
         ]. Patients treated with GIK had lower mean serum glucose concentrations in the perioperative period (138 versus 260 mg/dL [7.7 versus 14.4 mg/dL]). At two years, GIK patients had significantly lower rates of wound infections (1 versus 10 percent), recurrent ischemia (5 versus 19 percent), and mortality (2 versus 10 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a randomized trial [
         <a href="#rid76">
          76
         </a>
         ], 352 patients (with or without known diabetes) undergoing CABG were randomized to intensive glucose target (100 to 140 mg/dL) or to a conservative target (141 to 180 mg/dL). In the cohort with diabetes, there were no differences in the rates of complications in patients treated in the intensive or conservative group (49 versus 48 percent, p = 0.87). (See
         <a class="medical medical_review" href="/z/d/html/1585.html" rel="external">
          "Early noncardiac complications of coronary artery bypass graft surgery", section on 'Sternal wound infection and mediastinitis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1556.html" rel="external">
          "Coronary artery bypass surgery: Perioperative medical management", section on 'Glycemic control'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H29">
         <span class="h1">
          RECOMMENDATIONS OF OTHERS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our recommendations are similar to those from the American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society for Cardiovascular Angiography and Interventions/Society of Thoracic Surgeons in 2014 and those from the European Society of Cardiology/European Association for the Study of Diabetes in 2013 [
         <a href="#rid77">
          77-81
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H933943080">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/119297.html" rel="external">
          "Society guideline links: Percutaneous coronary intervention"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/119298.html" rel="external">
          "Society guideline links: Coronary artery bypass graft surgery"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H32">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The indications for revascularization in stable patients are similar for those with and without diabetes. (See
         <a class="local">
          'Indications for revascularization'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications
         </strong>
         – For patients with diabetes and stable angina who do not have a clear indication for revascularization, we suggest intensive medical therapy as the initial strategy rather than immediate revascularization (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). (See
         <a class="local">
          'Revascularization versus medical therapy for stable angina'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with diabetes and multivessel disease (particularly if it is complex) who require revascularization, we recommend CABG rather than percutaneous coronary intervention (PCI) (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). (See
         <a class="local">
          'PCI versus CABG'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with diabetes undergoing CABG, we suggest placement of bilateral, rather than single, internal thoracic artery (ITA) grafts (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). It is reasonable to not perform bilateral ITA grafting in individuals older than 70 to 75 years, as the survival benefit from bilateral ITA may be small in older individuals. (See
         <a class="local">
          'Internal thoracic artery grafts'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with diabetes who have recurrence of unacceptable angina after CABG, we suggest repeat revascularization with PCI for appropriate lesions (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Previous coronary artery bypass graft surgery'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with diabetes who undergo CABG, we suggest tight glycemic control intra- and postoperatively to improve both cardiac and noncardiac outcomes (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Intraoperative and postoperative glycemic control'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2811349696">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff thank Dr. Arie P. Kappetein for his past contributions as a section editor to prior versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Cavender MA, Steg PG, Smith SC Jr, et al. Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Circulation 2015; 132:923.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milojevic M, Serruys PW, Sabik JF 3rd, et al. Bypass Surgery or Stenting for Left Main Coronary Artery Disease in Patients With Diabetes. J Am Coll Cardiol 2019; 73:1616.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hammoud T, Tanguay JF, Bourassa MG. Management of coronary artery disease: therapeutic options in patients with diabetes. J Am Coll Cardiol 2000; 36:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Head SJ, Milojevic M, Daemen J, et al. Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. Lancet 2018; 391:939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thuijs DJFM, Kappetein AP, Serruys PW, et al. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial. Lancet 2019; 394:1325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           BARI 2D Study Group, Frye RL, August P, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009; 360:2503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaitman BR, Hardison RM, Adler D, et al. The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction. Circulation 2009; 120:2529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356:1503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maron DJ, Boden WE, Spertus JA, et al. Impact of metabolic syndrome and diabetes on prognosis and outcomes with early percutaneous coronary intervention in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial. J Am Coll Cardiol 2011; 58:131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brooks MM, Chaitman BR, Nesto RW, et al. Clinical and angiographic risk stratification and differential impact on treatment outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation 2012; 126:2115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newman JD, Anthopolos R, Mancini GBJ, et al. Outcomes of Participants With Diabetes in the ISCHEMIA Trials. Circulation 2021; 144:1380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perera D, Clayton T, O'Kane PD, et al. Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction. N Engl J Med 2022; 387:1351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathew V, Gersh BJ, Williams BA, et al. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 2004; 109:476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stein B, Weintraub WS, Gebhart SP, et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 1995; 91:979.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kip KE, Faxon DP, Detre KM, et al. Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1996; 94:1818.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suero JA, Marso SP, Jones PG, et al. Procedural outcomes and long-term survival among patients undergoing percutaneous coronary intervention of a chronic total occlusion in native coronary arteries: a 20-year experience. J Am Coll Cardiol 2001; 38:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehran R, Dangas GD, Kobayashi Y, et al. Short- and long-term results after multivessel stenting in diabetic patients. J Am Coll Cardiol 2004; 43:1348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elezi S, Kastrati A, Pache J, et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 1998; 32:1866.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Belle E, Bauters C, Hubert E, et al. Restenosis rates in diabetic patients: a comparison of coronary stenting and balloon angioplasty in native coronary vessels. Circulation 1997; 96:1454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rensing BJ, Hermans WR, Vos J, et al. Luminal narrowing after percutaneous transluminal coronary angioplasty. A study of clinical, procedural, and lesional factors related to long-term angiographic outcome. Coronary Artery Restenosis Prevention on Repeated Thromboxane Antagonism (CARPORT) Study Group. Circulation 1993; 88:975.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           West NE, Ruygrok PN, Disco CM, et al. Clinical and angiographic predictors of restenosis after stent deployment in diabetic patients. Circulation 2004; 109:867.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carrozza JP Jr, Kuntz RE, Fishman RF, Baim DS. Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. Ann Intern Med 1993; 118:344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schofer J, Schlüter M, Rau T, et al. Influence of treatment modality on angiographic outcome after coronary stenting in diabetic patients: a controlled study. J Am Coll Cardiol 2000; 35:1554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tada T, Kimura T, Morimoto T, et al. Comparison of three-year clinical outcomes after sirolimus-eluting stent implantation among insulin-treated diabetic, non-insulin-treated diabetic, and non-diabetic patients from j-Cypher registry. Am J Cardiol 2011; 107:1155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmed JM, Hong MK, Mehran R, et al. Influence of diabetes mellitus on early and late clinical outcomes in saphenous vein graft stenting. J Am Coll Cardiol 2000; 36:1186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mick MJ, Piedmonte MR, Arnold AM, Simpfendorfer C. Risk stratification for long-term outcome after elective coronary angioplasty: a multivariate analysis of 5,000 patients. J Am Coll Cardiol 1994; 24:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abizaid A, Kornowski R, Mintz GS, et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 1998; 32:584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Banning AP, Westaby S, Morice MC, et al. Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. J Am Coll Cardiol 2010; 55:1067.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salomon NW, Page US, Okies JE, et al. Diabetes mellitus and coronary artery bypass. Short-term risk and long-term prognosis. J Thorac Cardiovasc Surg 1983; 85:264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whang W, Bigger JT Jr. Diabetes and outcomes of coronary artery bypass graft surgery in patients with severe left ventricular dysfunction: results from The CABG Patch Trial database. The CABG Patch Trial Investigators and Coordinators. J Am Coll Cardiol 2000; 36:1166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borger MA, Rao V, Weisel RD, et al. Deep sternal wound infection: risk factors and outcomes. Ann Thorac Surg 1998; 65:1050.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furnary AP, Zerr KJ, Grunkemeier GL, Starr A. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg 1999; 67:352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peterson MD, Borger MA, Rao V, et al. Skeletonization of bilateral internal thoracic artery grafts lowers the risk of sternal infection in patients with diabetes. J Thorac Cardiovasc Surg 2003; 126:1314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Higgins TL, Estafanous FG, Loop FD, et al. Stratification of morbidity and mortality outcome by preoperative risk factors in coronary artery bypass patients. A clinical severity score. JAMA 1992; 267:2344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1997; 96:1761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morris JJ, Smith LR, Jones RH, et al. Influence of diabetes and mammary artery grafting on survival after coronary bypass. Circulation 1991; 84:III275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lawrie GM, Morris GC Jr, Glaeser DH. Influence of diabetes mellitus on the results of coronary bypass surgery. Follow-up of 212 diabetic patients ten to 15 years after surgery. JAMA 1986; 256:2967.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith LR, Harrell FE Jr, Rankin JS, et al. Determinants of early versus late cardiac death in patients undergoing coronary artery bypass graft surgery. Circulation 1991; 84:III245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen Y, Raz I, Merin G, Mozes B. Comparison of factors associated with 30-day mortality after coronary artery bypass grafting in patients with versus without diabetes mellitus. Israeli Coronary Artery Bypass (ISCAB) Study Consortium. Am J Cardiol 1998; 81:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thourani VH, Weintraub WS, Stein B, et al. Influence of diabetes mellitus on early and late outcome after coronary artery bypass grafting. Ann Thorac Surg 1999; 67:1045.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeBakey ME, Glaeser DH. Patterns of atherosclerosis: effect of risk factors on recurrence and survival-analysis of 11,890 cases with more than 25-year follow-up. Am J Cardiol 2000; 85:1045.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sprecher DL, Pearce GL. How deadly is the "deadly quartet"? A post-CABG evaluation. J Am Coll Cardiol 2000; 36:1159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farkouh ME, Domanski M, Sleeper LA, et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 2012; 367:2375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mack MJ, Banning AP, Serruys PW, et al. Bypass versus drug-eluting stents at three years in SYNTAX patients with diabetes mellitus or metabolic syndrome. Ann Thorac Surg 2011; 92:2140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moussa I, Leon MB, Baim DS, et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 2004; 109:2273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baumgart D, Klauss V, Baer F, et al. One-year results of the SCORPIUS study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients. J Am Coll Cardiol 2007; 50:1627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jiménez-Quevedo P, Sabaté M, Angiolillo DJ, et al. Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial. Eur Heart J 2007; 28:1946.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kirtane AJ, Ellis SG, Dawkins KD, et al. Paclitaxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials. J Am Coll Cardiol 2008; 51:708.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stettler C, Allemann S, Wandel S, et al. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ 2008; 337:a1331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356:1030.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sabaté M, Jiménez-Quevedo P, Angiolillo DJ, et al. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation 2005; 112:2175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bangalore S, Kumar S, Fusaro M, et al. Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomised trials. BMJ 2012; 345:e5170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahmud E, Bromberg-Marin G, Palakodeti V, et al. Clinical efficacy of drug-eluting stents in diabetic patients: a meta-analysis. J Am Coll Cardiol 2008; 51:2385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee SW, Park SW, Kim YH, et al. A randomized comparison of sirolimus- versus Paclitaxel-eluting stent implantation in patients with diabetes mellitus. J Am Coll Cardiol 2008; 52:727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee SW, Park SW, Kim YH, et al. A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus: 4-year clinical outcomes of DES-DIABETES (drug-eluting stent in patients with DIABETES mellitus) trial. JACC Cardiovasc Interv 2011; 4:310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stone GW, Rizvi A, Newman W, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010; 362:1663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaul U, Bangalore S, Seth A, et al. Paclitaxel-Eluting versus Everolimus-Eluting Coronary Stents in Diabetes. N Engl J Med 2015; 373:1709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stone GW, Kedhi E, Kereiakes DJ, et al. Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. Circulation 2011; 124:893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bangalore S, Toklu B, Patel N, et al. Newer-Generation Ultrathin Strut Drug-Eluting Stents Versus Older Second-Generation Thicker Strut Drug-Eluting Stents for Coronary Artery Disease. Circulation 2018; 138:2216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Waksman R, Shlofmitz E, Windecker S, et al. Efficacy and Safety of Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin, Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization of Patients With Diabetes Mellitus. Am J Cardiol 2019; 124:1020.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corpus RA, George PB, House JA, et al. Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. J Am Coll Cardiol 2004; 43:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishio K, Sakurai M, Kusuyama T, et al. A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. Diabetes Care 2006; 29:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi D, Kim SK, Choi SH, et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 2004; 27:2654.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adler DS, Goldman L, O'Neil A, et al. Long-term survival of more than 2,000 patients after coronary artery bypass grafting. Am J Cardiol 1986; 58:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leavitt BJ, Sheppard L, Maloney C, et al. Effect of diabetes and associated conditions on long-term survival after coronary artery bypass graft surgery. Circulation 2004; 110:II41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marso SP, Ellis SG, Gurm HS, et al. Proteinuria is a key determinant of death in patients with diabetes after isolated coronary artery bypass grafting. Am Heart J 2000; 139:939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Halkos ME, Puskas JD, Lattouf OM, et al. Elevated preoperative hemoglobin A1c level is predictive of adverse events after coronary artery bypass surgery. J Thorac Cardiovasc Surg 2008; 136:631.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Momin AU, Deshpande R, Potts J, et al. Incidence of sternal infection in diabetic patients undergoing bilateral internal thoracic artery grafting. Ann Thorac Surg 2005; 80:1765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agrifoglio M, Trezzi M, Barili F, et al. Double vs single internal thoracic artery harvesting in diabetic patients: role in perioperative infection rate. J Cardiothorac Surg 2008; 3:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dorman MJ, Kurlansky PA, Traad EA, et al. Bilateral internal mammary artery grafting enhances survival in diabetic patients: a 30-year follow-up of propensity score-matched cohorts. Circulation 2012; 126:2935.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Puskas JD, Sadiq A, Vassiliades TA, et al. Bilateral internal thoracic artery grafting is associated with significantly improved long-term survival, even among diabetic patients. Ann Thorac Surg 2012; 94:710.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaudino M, Benedetto U, Fremes S, et al. Radial-Artery or Saphenous-Vein Grafts in Coronary-Artery Bypass Surgery. N Engl J Med 2018; 378:2069.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furnary AP, Gao G, Grunkemeier GL, et al. Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 2003; 125:1007.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lazar HL, Chipkin SR, Fitzgerald CA, et al. Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events. Circulation 2004; 109:1497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benedetto U, Gaudino M, Caputo M, et al. Right internal thoracic artery versus radial artery as the second best arterial conduit: Insights from a meta-analysis of propensity-matched data on long-term survival. J Thorac Cardiovasc Surg 2016; 152:1083.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Umpierrez G, Cardona S, Pasquel F, et al. Randomized Controlled Trial of Intensive Versus Conservative Glucose Control in Patients Undergoing Coronary Artery Bypass Graft Surgery: GLUCO-CABG Trial. Diabetes Care 2015; 38:1665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012; 126:e354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2012; 126:3097.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2014; 64:1929.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Authors/Task Force members, Windecker S, Kolh P, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35:2541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41:255.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1581 Version 45.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26152709" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30947913" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Bypass Surgery or Stenting for Left Main Coronary Artery Disease in Patients With Diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10933343" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Management of coronary artery disease: therapeutic options in patients with diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29478841" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31488373" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19502645" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : A randomized trial of therapies for type 2 diabetes and coronary artery disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19920001" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17387127" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Optimal medical therapy with or without PCI for stable coronary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21718908" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Impact of metabolic syndrome and diabetes on prognosis and outcomes with early percutaneous coronary intervention in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23008442" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Clinical and angiographic risk stratification and differential impact on treatment outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34521217" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Outcomes of Participants With Diabetes in the ISCHEMIA Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36027563" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14732749" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7850985" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8873655" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11499731" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Procedural outcomes and long-term survival among patients undergoing percutaneous coronary intervention of a chronic total occlusion in native coronary arteries: a 20-year experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15093865" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Short- and long-term results after multivessel stenting in diabetic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9857865" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9315531" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Restenosis rates in diabetic patients: a comparison of coronary stenting and balloon angioplasty in native coronary vessels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8353925" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Luminal narrowing after percutaneous transluminal coronary angioplasty. A study of clinical, procedural, and lesional factors related to long-term angiographic outcome. Coronary Artery Restenosis Prevention on Repeated Thromboxane Antagonism (CARPORT) Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14757691" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Clinical and angiographic predictors of restenosis after stent deployment in diabetic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8430980" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10807460" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Influence of treatment modality on angiographic outcome after coronary stenting in diabetic patients: a controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21296326" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Comparison of three-year clinical outcomes after sirolimus-eluting stent implantation among insulin-treated diabetic, non-insulin-treated diabetic, and non-diabetic patients from j-Cypher registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11028469" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Influence of diabetes mellitus on early and late clinical outcomes in saphenous vein graft stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8006285" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Risk stratification for long-term outcome after elective coronary angioplasty: a multivariate analysis of 5,000 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9741497" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20079596" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6600508" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Diabetes mellitus and coronary artery bypass. Short-term risk and long-term prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11028466" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Diabetes and outcomes of coronary artery bypass graft surgery in patients with severe left ventricular dysfunction: results from The CABG Patch Trial database. The CABG Patch Trial Investigators and Coordinators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9564926" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Deep sternal wound infection: risk factors and outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10197653" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14666001" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Skeletonization of bilateral internal thoracic artery grafts lowers the risk of sternal infection in patients with diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1564774" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Stratification of morbidity and mortality outcome by preoperative risk factors in coronary artery bypass patients. A clinical severity score.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9323059" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1934420" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Influence of diabetes and mammary artery grafting on survival after coronary bypass.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3534339" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Influence of diabetes mellitus on the results of coronary bypass surgery. Follow-up of 212 diabetic patients ten to 15 years after surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1934415" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Determinants of early versus late cardiac death in patients undergoing coronary artery bypass graft surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9462597" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Comparison of factors associated with 30-day mortality after coronary artery bypass grafting in patients with versus without diabetes mellitus. Israeli Coronary Artery Bypass (ISCAB) Study Consortium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10320249" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Influence of diabetes mellitus on early and late outcome after coronary artery bypass grafting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10781750" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Patterns of atherosclerosis: effect of risk factors on recurrence and survival-analysis of 11,890 cases with more than 25-year follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11028465" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : How deadly is the "deadly quartet"? A post-CABG evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23121323" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Strategies for multivessel revascularization in patients with diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21967819" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Bypass versus drug-eluting stents at three years in SYNTAX patients with diabetes mellitus or metabolic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15123524" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17950142" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : One-year results of the SCORPIUS study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17562666" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18279734" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Paclitaxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18757996" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17296823" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16203930" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22885395" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomised trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18565394" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Clinical efficacy of drug-eluting stents in diabetic patients: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18718419" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : A randomized comparison of sirolimus- versus Paclitaxel-eluting stent implantation in patients with diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21435609" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus: 4-year clinical outcomes of DES-DIABETES (drug-eluting stent in patients with DIABETES mellitus) trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20445180" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26466202" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Paclitaxel-Eluting versus Everolimus-Eluting Coronary Stents in Diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21824922" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29945934" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Newer-Generation Ultrathin Strut Drug-Eluting Stents Versus Older Second-Generation Thicker Strut Drug-Eluting Stents for Coronary Artery Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31353004" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Efficacy and Safety of Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin, Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization of Patients With Diabetes Mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14715174" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16373904" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15505001" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3488671" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Long-term survival of more than 2,000 patients after coronary artery bypass grafting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15364836" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Effect of diabetes and associated conditions on long-term survival after coronary artery bypass graft surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10827372" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Proteinuria is a key determinant of death in patients with diabetes after isolated coronary artery bypass grafting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18805264" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Elevated preoperative hemoglobin A1c level is predictive of adverse events after coronary artery bypass surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16242453" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Incidence of sternal infection in diabetic patients undergoing bilateral internal thoracic artery grafting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18573201" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Double vs single internal thoracic artery harvesting in diabetic patients: role in perioperative infection rate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23166212" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Bilateral internal mammary artery grafting enhances survival in diabetic patients: a 30-year follow-up of propensity score-matched cohorts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22677228" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Bilateral internal thoracic artery grafting is associated with significantly improved long-term survival, even among diabetic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29708851" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Radial-Artery or Saphenous-Vein Grafts in Coronary-Artery Bypass Surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12771873" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15006999" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27342731" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Right internal thoracic artery versus radial artery as the second best arterial conduit: Insights from a meta-analysis of propensity-matched data on long-term survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26180108" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Randomized Controlled Trial of Intensive Versus Conservative Glucose Control in Patients Undergoing Coronary Artery Bypass Graft Surgery: GLUCO-CABG Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23166211" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23166210" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25077860" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25173339" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31497854" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
